Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03633084 · ClinicalTrials.gov registry record · Phase 1

RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration

A Phase 1 study of Age-related Macular Degeneration, sponsored by Ribomic USA.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
4
Study locations

NCT03633084: Completed Phase 1 study of Age-related Macular Degeneration, sponsored by Ribomic USA.

NCT03633084 is a Phase 1 study of Age-related Macular Degeneration that has completed, run by Ribomic USA. The registered enrollment target is 9 participants, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03633084, a Phase 1 study of Age-related Macular Degeneration, has completed, sponsored by Ribomic USA.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
4
Study locations

Study Summary

This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related macular degeneration.

Primary Outcome

Biomicroscopy is used by an ophthalmologist to assess the health of the front of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.

Conditions Studied

Age-related Macular Degeneration

Interventions

  • DRUG RBM-007 Injectable Solution

Study Locations (4)

California

  • Retinal Consultants Medical Group - Sacramento
  • Retinal Consultants Medical Group - Sacramento
  • Stanford University - Stanford
  • Bay Area Retina Associates - Walnut Creek

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2018-08-29
Est. Completion 2019-06-26
Phase Phase 1
Ribomic USA

3 total trials

What the finished NCT03633084 record still lists

NCT03633084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which RBM-007 Injectable Solution is the first listed.

NCT03633084 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03633084 about?

NCT03633084 is a clinical study titled "RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration". This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related macular degeneration.

What is the current status of trial NCT03633084?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-08-29. Estimated completion is 2019-06-26.

What conditions does trial NCT03633084 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration.

What interventions are being tested in trial NCT03633084?

The interventions under investigation include: RBM-007 Injectable Solution (DRUG).

Who is sponsoring clinical trial NCT03633084?

This trial is sponsored by Ribomic USA, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03633084 being conducted?

This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03633084's enrollment target sits among peer trials

9 73rd of 74 the lowest of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03633084, the US trial registry maintained by the National Library of Medicine. NCT03633084 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.